Ramipril: meta-analysis of COVID-19 studies

Meta-analysis1 study · 114 patientsc19early.org

Ramipril for COVID-19

Serious outcome risk
Ramipril
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−144%
Mortality (1)−144%
Ventilation (1)−289%
ICU admission (1)−289%
RCTs (1)−144%
Late (1)−144%
00.511.5+
← Ramipril
reduces risk
Increased
risk →
October 2026

Ramipril COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−289%3.89 · 0.19–78.902/790/35289% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.38
All studies−289%3.89 · 0.19–78.902/790/35289% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−289%3.89 · 0.19–78.902/790/35289% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.38
All studies−289%3.89 · 0.19–78.902/790/35289% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3800.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →
October 2026

Ramipril COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.59
All studies−144%2.44 · 0.10–58.541/790/35144% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5900.511.52+
Rotate screen for more detailsIncrease width for more details
← Ramipril
reduces risk
Ramipril
increases risk →